Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors

NCT04362748 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04362748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04362748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
September 15, 2020
Completion date
September 21, 2023
Enrollment
34 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors